Real-world Patient characteristics, Treatment Patterns and Costs in Relapsing Multiple Sclerosis Patients Treated With Glatiramer acetate, Dimethyl Fumarate Or Teriflunomide in Germany

References

• Ohlmeier C , GotheH, HaasJet al. Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: real world evidence based on German claims data. PLoS ONE, 15(5), e0231846 (2020).
   PubMed Web of Science ®Google Scholar
• Li H , HuF, ZhangY, LiK. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. J. Neurol., 267(12), 3489–3498 (2020).
   PubMed Web of Science ®Google Scholar
• Jongen PJ . Health-related quality of life in patients with multiple sclerosis: impact of disease-modifying drugs. CNS Drugs, 31(7), 585–602 (2017).
   PubMed Web of Science ®Google Scholar
• Cramer JA , RoyA, BurrellAet al. Medication compliance and persistence: terminology and definitions. Value Health, 11(1), 44–47 (2008).
   PubMed Web of Science ®Google Scholar
• Kern S , ReichmannH, ZiemssenT. Therapieadhärenz in der neurologischen Praxis. Beispiel: Multiple Sklerose [Adherence to neurologic treatment. Lessons from multiple sclerosis]. Nervenarzt, 79(8), 877–878 (2008).
   PubMed Web of Science ®Google Scholar
• Haase R , KullmannJS, ZiemssenT. Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS survey. Ther. Adv. Neurol. Disord., 9(4), 250–263 (2016).
   PubMed Web of Science ®Google Scholar
• Guerci B , ChananN, KaurS, Jasso-MosquedaJG, LewE. Lack of treatment persistence and treatment nonadherence as barriers to glycaemic control in patients with type 2 diabetes. Diabetes Ther., 10(2), 437–449 (2019).
   PubMed Web of Science ®Google Scholar
• Hobson EV , SharrackB. Emerging oral disease-modifying therapies in multiple sclerosis: a review of the latest clinical evidence. Clin. Invest., 1(7), 1049–1058 (2011).
   Google Scholar
• Becker V , HeeschenV, SchuhK, SchiebH, ZiemssenT. Patient satisfaction and healthcare services in specialized multiple sclerosis centres in Germany. Ther. Adv. Neurol. Disord., 11, https://doi.org/10.1177/1756285617748845 (2018).
   PubMed Web of Science ®Google Scholar
• Duquette P , YeungM, MouallifS, NakhaipourHR, HaddadP, SchecterR. A retrospective claims analysis: compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies. PLoS ONE, 14(1), e0210417 (2019).
   PubMed Web of Science ®Google Scholar
• Jonker MF , DonkersB, GoossensLMAet al. Summarizing patient preferences for the competitive landscape of multiple sclerosis treatment options. Med. Decis. Making, 40(2), 198–211 (2020).
   PubMed Web of Science ®Google Scholar
• Bergvall N , PetrillaAA, KarkareSUet al. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. J. Med. Econ., 17(10), 696–707 (2014).
   PubMedGoogle Scholar
• Johnson KM , ZhouH, LinF, KoJJ, HerreraV. Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year. J. Manag. Care Spec. Pharm., 23(8), 844–852 (2017).
   PubMedGoogle Scholar
• Santoleri F , LasalaR, LogrecoA, ElHassani M, CostantiniA. Medication adherence, persistence and cost in multiple sclerosis patients: oral vs parenteral treatment. Int. J. Pharm. Sci. Res., 3, 117 (2016).
   Google Scholar
• Treadaway K , CutterG, SalterAet al. Factors that influence adherence with disease-modifying therapy in MS. J. Neurol., 256(4), 568–576 (2009).
   PubMed Web of Science ®Google Scholar
• Burks J , MarshallTS, YeX. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis. Clinicoecon. Outcomes Res., 9, 251–260 (2017).
   PubMed Web of Science ®Google Scholar
• Gerber B , CowlingT, ChenG, YeungM, DuquetteP, HaddadP. The impact of treatment adherence on clinical and economic outcomes in multiple sclerosis: real world evidence from Alberta, Canada. Mult. Scler. Relat. Disord., 18, 218–224 (2017).
   PubMed Web of Science ®Google Scholar
• Ziemssen T , HillertJ, ButzkuevenH. The importance of collecting structured clinical information on multiple sclerosis. BMC Med., 14, 81 (2016).
   PubMed Web of Science ®Google Scholar
• Katkade VB , SandersKN, ZouKH. Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. J. Multidiscip. Healthc., 11, 295–304 (2018).
   PubMed Web of Science ®Google Scholar
• Alexander JK , ArielyR, WuYet al. Treatment patterns following initiation of generic glatiramer acetate among patients with multiple sclerosis from two large real-world databases in the United States. Curr. Med. Res. Opin., 37(8), 1323–1329 (2021).
   PubMed Web of Science ®Google Scholar
• Petersen G , WittmannR, ArndtV, GöpffarthD. Epidemiologie der Multiplen Sklerose in Deutschland: Regionale Unterschiede und Versorgungsstruktur in Abrechnungsdaten der gesetzlichen Krankenversicherung [Epidemiology of multiple sclerosis in Germany: regional differences and drug prescription in the claims data of the statutory health insurance]. Nervenarzt, 85(8), 990–998 (2014).
   PubMed Web of Science ®Google Scholar
• Höer A , SchiffhorstG, ZimmermannAet al. Multiple sclerosis in Germany: data analysis of administrative prevalence and healthcare delivery in the statutory health system. BMC Health Serv. Res., 14, 381 (2014).
   PubMed Web of Science ®Google Scholar
• Neusser S , BiermannJ, LuxG, WasemJ, ReissnerV, NeumannA. Economic burden of multiple sclerosis to the social insurance system in Germany. J. Public Health, 26, 271–278 (2018).
   Google Scholar
• Simbrich A , ThibautJ, KhilL, BergerK, RiedelO, SchmedtN. Drug-use patterns and severe adverse events with disease-modifying drugs in patients with multiple sclerosis: a cohort study based on German claims data. Neuropsychiatr. Dis. Treat., 15, 1439–1457 (2019).
   PubMed Web of Science ®Google Scholar
• Watson C , ProsserC, BraunS, Landsman-BlumbergPB, GleissnerE, NaoshyS. Health care resource utilization before and after natalizumab initiation among patients with multiple sclerosis in Germany. Clinicoecon. Outcomes Res., 9, 85–97 (2017).
   PubMed Web of Science ®Google Scholar
• Ziemssen T , ProsserC, HaasJSet al. Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment. BMC Neurol., 17(1), 62 (2017).
   PubMedGoogle Scholar
• Comi G , AmatoMP, BertolottoAet al. The heritage of glatiramer acetate and its use in multiple sclerosis. Mult. Scler. Demyelinating Disord., 1, 6 (2016).
   Google Scholar
• Melamed-Gal S , LoupeP, TimanBet al. Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone. eNeurologicalSci., 12, 19–30 (2018).
   PubMedGoogle Scholar
• European Multiple Sclerosis Platform . MS facts and MS treatments (2019). http://www.emsp.org/about-ms/ms-treatments/
   Google Scholar
• Braune S , GrimmS, van HövellPet al. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry. J. Neurol., 265(12), 2980–2992 (2018).
   PubMed Web of Science ®Google Scholar
• Andersohn F , WalkerJ. Characteristics and external validity of the German Health Risk Institute (HRI) Database. Pharmacoepidemiol. Drug Saf., 25(1), 106–109 (2016).
   PubMed Web of Science ®Google Scholar
• Quan H , LiB, CourisCMet al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am. J. Epidemiol., 173(6), 676–682 (2011).
   PubMed Web of Science ®Google Scholar
• Ollendorf DA , JilinskaiaE, Oleen-BurkeyM. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J. Manag. Care Pharm., 8(6), 469–476 (2002).
   PubMedGoogle Scholar
• Chastek BJ , Oleen-BurkeyM, Lopez-BresnahanMV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J. Med. Econ., 13(4), 618–625 (2010).
   PubMedGoogle Scholar
• Kern DM , CepedaMS. Treatment patterns and comorbid burden of patients newly diagnosed with multiple sclerosis in the United States. BMC Neurol., 20(1), 296 (2020).
   PubMed Web of Science ®Google Scholar
• Halpern R , AgarwalS, DembekC, BortonL, Lopez-BresnahanM. Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis. Patient Prefer. Adherence, 5, 73–84 (2011).
   PubMed Web of Science ®Google Scholar
• Yermakov S , DavisM, CalnanMet al. Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis. J. Med. Econ., 18(9), 711–720 (2015).
   PubMed Web of Science ®Google Scholar
• Burks J , MarshallTS, YeX. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis. Clinicoecon. Outcomes Res., 9, 251–260 (2017).
   PubMed Web of Science ®Google Scholar
• Kawachi I , OkamotoS, SakamotoMet al. Recent transition of medical cost and relapse rate of multiple sclerosis in Japan based on analysis of a health insurance claims database. BMC Neurol., 19(1), 324 (2019).
   PubMed Web of Science ®Google Scholar
• Freeman L , KeeA, TianM, MehtaR. Evaluating treatment patterns, relapses, healthcare resource utilization, and costs associated with disease-modifying treatments for multiple sclerosis in DMT naive patients. Clinicoecon. Outcomes Res., 13, 65–75 (2021).
   PubMed Web of Science ®Google Scholar
• Boster A , NicholasJ, WuNet al. Comparative effectiveness research of disease-modifying therapies for the management of multiple sclerosis: analysis of a large health insurance claims database. Neurol. Ther., 6(1), 91–102 (2017).
   PubMed Web of Science ®Google Scholar
• Weih M , RoßnagelF, DikowH, WehrleK, BrauneS, BergmannA. Daten zur Multiplen Sklerose in Deutschland und ihre Abbildung im Register des ambulanten Netzwerkes NeuroTransData (NTD) [Data on multiple sclerosis in Germany and their representation in the ambulatory registry NeuroTransData (NTD) network]. Fortschr. Neurol. Psychiatr., 88(6), 379–385 (2020).
   PubMed Web of Science ®Google Scholar
• Munsell M , FreanM, MenzinJ, PhillipsAL. An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug. Patient Prefer. Adherence, 11, 55–62 (2016).
   PubMed Web of Science ®Google Scholar
• Agashivala N , WuN, AbouzaidSet al. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. BMC Neurol., 13, 138 (2013).
   PubMed Web of Science ®Google Scholar
• Kim SJ , KwonOD, HanEBet al. Impact of number of medications and age on adherence to antihypertensive medications: a nationwide population-based study. Medicine (Baltimore), 98(49), e17825 (2019).
   PubMed Web of Science ®Google Scholar
• Lenz F , HarmsL. The impact of patient support programs on adherence to disease-modifying therapies of patients with relapsing-remitting multiple sclerosis in Germany: a non-interventional, prospective study. Adv. Ther., 37(6), 2999–3009 (2020).
   PubMed Web of Science ®Google Scholar
• Bomprezzi R . Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview. Ther. Adv. Neurol. Disord., 8(1), 20–30 (2015).
   PubMed Web of Science ®Google Scholar
• Scott LJ . Teriflunomide: a review in relapsing-remitting multiple sclerosis. Drugs, 79(8), 875–886 (2019).
   PubMed Web of Science ®Google Scholar
• Nicholas J , BosterA, WuNet al. Comparison of disease-modifying therapies for the management of multiple sclerosis: analysis of healthcare resource utilization and relapse rates from US insurance claims data. Pharmacoecon. Open, 2(1), 31–41 (2018).
   PubMedGoogle Scholar
• Blozik E , RapoldR, EichlerK, ReichO. Epidemiology and costs of multiple sclerosis in Switzerland: an analysis of health-care claims data, 2011–2015. Neuropsychiatr. Dis. Treat., 13, 2737–2745 (2017).
   PubMed Web of Science ®Google Scholar
• Moccia M , LopertoI, LanzilloRet al. Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy). BMC Health Serv. Res., 20(1), 797 (2020).
   PubMed Web of Science ®Google Scholar
• Petruzzo M , PalladinoR, NardoneAet al. The impact of diagnostic criteria and treatments on the 20-year costs for treating relapsing-remitting multiple sclerosis. Mult. Scler. Relat. Disord., 38, 101514 (2020).
   PubMed Web of Science ®Google Scholar
• Müller S , ZiemssenT, DiehmCet al. How to implement adherence-promoting programs in clinical practice? A discrete choice experiment on physicians’ preferences. Patient Prefer. Adherence, 14, 267–276 (2020).
   PubMed Web of Science ®Google Scholar
• Bourdin A , DuboisJ, FoleyRA, SchluepM, BugnonO, BergerJ. Satisfaction and experiences of patients taking fingolimod and involved in a pharmacy-based patient support program in Switzerland – a qualitative study. BMC Health Serv. Res., 20(1), 425 (2020).
   PubMed Web of Science ®Google Scholar